FDA

Provectus Biopharmaceuticals, Inc. (Provectus) has unveiled VisiRose, Inc. (VisiRose), marking its venture into founded entities. This newly established clinical-stage biotech firm is dedicated to advancing the commercialization of Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT) targeting infectious keratitis and other […]

Microbot Medical Inc, an innovative medical technology firm still in the pre-commercial phase, is dedicated to enhancing patient and provider care on a global scale. The company has developed the pioneering LIBERTY, a single-use endovascular robotic system, and has now

Eikonizo Therapeutics Gains Financial Backing from Novo Nordisk for Its Prime Candidate, EKZ-102 Eikonizo Therapeutics, a groundbreaking biopharmaceutical company committed to creating disease-altering treatments for those suffering from neurodegenerative and cardiorenal conditions, has declared a successful equity investment from Novo

Across the UK, patients will have increased access to innovative treatments and clinical trials with the announcement of a £100 million public-private investment aimed at establishing 20 research centres. Commercial Research Delivery Centres (CRDCs) are set to serve as regional

AstraZeneca in collaboration with Merck—recognized as MSD outside the US and Canada—has unveiled enduring data from the OlympiA phase 3 trial, demonstrating that Lynparza (olaparib) achieves long-lasting, meaningful clinical improvements in overall survival (OS), invasive disease-free survival (IDFS), and distant

Insights from the World Health Organization (WHO) indicate that approximately 2.2 billion malaria cases and 12.7 million deaths have been prevented since the year 2000. Despite this progress, malaria continues to pose a significant global health challenge, with the WHO

Researchers at the National Institute of Health (NIH) have unveiled groundbreaking insights into the mechanism by which low-density lipoprotein cholesterol (LDL-C), commonly referred to as “bad” cholesterol, accumulates in the body. For the first time, scientists demonstrated how the structural

NEC Bio Therapeutics, a company at the forefront of clinical strategy and trial management in oncology, has showcased impressive interim outcomes from a 24-week phase 1 trial of NECVAX-NEO1. This orally administered cancer vaccine, designed to work in tandem with

Asahi Kasei Pharma has advanced its evolution into a global specialty pharmaceuticals leader through a new licensing deal with Chiome Bioscience for a humanized anti-CX3CR1 antibody. This collaboration exemplifies the Open Innovation initiative at Asahi Kasei Pharma, which focuses on

Bayer Announces Strategic Acquisition In a recent announcement, Bayer revealed their plans to purchase HiDoc Technologies GmbH by early 2025, along with initiating the market launch of the Cara Care app. This digital health application is uniquely tailored for individuals